ROYALTY CONVERSION AGREEMENTRoyalty Conversion Agreement • November 13th, 2012 • Arrayit Diagnostics, Inc. • Texas
THIS ROYALTY CONVERSION AGREEMENT (this “Agreement”), dated as of March 5, 2012, by and among Arrayit Corporation, a Nevada corporation, (“Arrayit”), Ovarian Cancer Testing, LLP, a Nevada limited liability limited partnership (the “Partnership”) and Arrayit Diagnostics, a Nevada corporation, (the “Company”) and the partners listed on Schedule I attached hereto (individually, a “Royalty holder” or collectively “Royalty holders”). Arrayit, Ovarian, the Partnership, the Company and the Royal holders and individually referred to as a “Party” and collectively as the “Parties.”
